for September 2018
Three reason to protect our sovereign southern border.
— David A. Clarke, Jr. (@SheriffClarke) September 3, 2018
1) Domestic and Foreign security threats
2)Prevent the Spread of Infectious diseases
3)Control a heavy influx of another country’s ne’er-do-wells
Here is EVIDENCE of reason number 2.
AMERICA FIRSThttps://t.co/WYS6Cx1eWH
NEW🔥in CID by @Crasspofungin @DosingMatters
— Antibiotic Steward (@ABsteward) September 14, 2018
Renal Dosing of Antibiotics: Are We Jumping the Gun?
The authors suggested that deferred renal dose reduction of wide therapeutic index antibiotics could improve outcomes in patients with infectious diseases. https://t.co/Cnu5et1tfb pic.twitter.com/LYq4jnCBXN
MERINO trial results released in JAMA today: Effect of Piperacillin-Tazobactam vs Meropenem in Escherichia coli or Klebsiella pneumoniae Infection https://t.co/O103BNnWTS
— David Paterson (@davidantibiotic) September 11, 2018
NEW A must read🔥@BSACandJAC @Crasspofungin @DosingMatters/
— Antibiotic Steward (@ABsteward) September 7, 2018
Dosing vancomycin in the super obese: less is more
Doses >4500 mg/day were not required to achieve pharmacodynamic AUC targets in obese & super obese patients at clinically relevant values of CLV.https://t.co/LkY7iWKhal pic.twitter.com/iK2K5Eu3n3
🔥Our new meta-analysis of 8 RCTs found > superinfection👾 with carbapenems vs. other Abx, including antipseudomonal b-lactams. It is NOT theoretical & adds more evidence to reserve🔐 carbapenems
— Antibiotic Tweets (@khalideljaaly) September 7, 2018
Link: https://t.co/uXD5jMZ22m
Interview by @Contagion_Live https://t.co/yAufzioXJB pic.twitter.com/Q4X4Xqezzz
Breaking news 🆔 📢📢
— Antibiotic Steward (@ABsteward) September 11, 2018
ZERBAXA® (ceftolozane and tazobactam) Met 1ry Endpoints of Non-Inferiority Vs. Meropenem in ASPECT-NP Study of Adult Patients with HAP & VAP Merck Plans to Submit Supplemental NDAs in the US & EU @SIDPharm @accpinfdprn @IDstewardship https://t.co/0cIvwXIfor
😃 I am excited to share the first of a new series here! @ABsteward and I will be doing a monthly roundup of journal articles. Here is August 2018! 📲 https://t.co/JFDsez4raK
— Tim Gauthier (@IDstewardship) September 14, 2018
Did we miss one? 💬 Let us know!!!
cc: @BSACandJAC @nimmyishot @SIDPharm @accpinfdprn @khalideljaaly pic.twitter.com/3us8wrnSXL
Very important topic: shared 💬💬decision making & antimicrobial stewardship. New data out of @BSACandJAC here 📲 https://t.co/sSOvuFeOdk Teamwork really does make the dream work! #SaveABX #Healthcare
— Tim Gauthier (@IDstewardship) September 1, 2018
cc: @ASCPharm @ASCP_Chicago @DASON_duke @StanfordASP @IDSAInfo @JasonGNewland pic.twitter.com/ZRPuWR35qw
A game change 🔥A NEW multi-center large prospective cohort study in CID :
— Antibiotic Steward (@ABsteward) September 11, 2018
The rate of SSI among pts receiveing cephalosporin-based prophylaxis is >2 times ⬆️ in carriers of ESBL-producing Enterobacteriaceae than non carriers after colorectal surgery. https://t.co/3PLJtrGpHB pic.twitter.com/EBsISrE5ND
Recommendations for stewardship human resources personnel in an acute care hospital setting in Canada. Read more NEW article in @ARICJournal by @ASPphysician
— Antibiotic Steward (@ABsteward) September 1, 2018
Et Al.
What do you think? @SIDPharm @accpinfdprn #idprn #pharmacists #antibioticstewardship https://t.co/i31VALAp0h pic.twitter.com/criiIgEu5M
New in @JAMA_current
— Antibiotic Steward (@ABsteward) September 16, 2018
Time has come to balance the recommendation for early and aggressive antibiotics for all patients with possible #sepsis with the diagnostic uncertainty regarding sepsis and the possible harm associated with unnecessary antibiotics.https://t.co/SdR6DwJUWL pic.twitter.com/sd8Ga6eAf7
Short and sweet video about appropriate antibiotic use in the outpatient setting by @BrettBarrettRPh https://t.co/TdlDpgDU3H
— Brad Langford (@BRxAD) September 29, 2018
What are some of the best #antimicrobialstewardship videos you've seen targeted at patients or clinicians? 🙏 pic.twitter.com/IZ0EWS7Do3
A NEW 🔥🔥 study in 🇳🇴 by @e_charani et Al in @BioMedCentral
— Antibiotic Steward (@ABsteward) September 10, 2018
The effect of antibiotic stewardship interventions with stakeholder involvement in hospital settings: a multicentre, cluster randomized controlled intervention study. #aricjournal https://t.co/ObZsLjMgzj pic.twitter.com/7vky4ue7ee
NEW🔥By @DrDrayMBA et Al @PharmacoJournal
— Antibiotic Steward (@ABsteward) September 3, 2018
Incidence of AKI among patients receiving the combination of vancomycin&piperacillin‐tazobactam or meropenem in acutely ill adults
VAN/PTZ was associated with 6.8‐fold ⬆️ risk developing AKI compared to VAN/MER. https://t.co/TbEgzmZ3kJ pic.twitter.com/dVTSDZhKox
“Overdiagnosis and overtreatment of [Lyme disease] is worsening, and health authorities should investigate this phenomenon.” 75% patients in this study of patients seeking treatment for chronic Lyme disease were IgG negative. https://t.co/RXhMrMcEz8
— Michael Calderwood (@CalderwoodMD) September 24, 2018
NEW🔥 :Predictive factors for MDR G- bacteria among hospitalised patients with complicated UTI.
— Antibiotic Steward (@ABsteward) September 18, 2018
Male gender 👨
Acquisition of cUTI in a medical care facility 🏥
UTI with/in 1yr & U. Cath 💦
Antibiotic treatment within the previous 30 days 💉https://t.co/UgPvs3WpAN pic.twitter.com/dMSwBg4lTe
DYK that 9/10 reported penicillin allergies are not true allergies, & using 2nd line abx for reported penicillin allergies leads to higher costs, mortality and surgical site infections? #AllergyEmancipation #antimicrobialstewardship @dan_diekema https://t.co/9D8quSvAqC
— Jasmine R Marcelin, MD (@DrJRMarcelin) September 24, 2018
NEW 🔥 in @BSACandJAC By Dr. David livermore. A must read article!
— Antibiotic Steward (@ABsteward) September 20, 2018
Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL- and AmpC-producing Enterobacteriaceae. #JACnews https://t.co/JnxoVlXBLb pic.twitter.com/atcmxnfvwO
NEW Study in OFID🔥 by @SIDPharm @ClaeysKcclaeys @emilylheil
— Antibiotic Steward (@ABsteward) September 15, 2018
A proposed ASP/RDT(Verigene®) Blood-Culture Gram - VE Treatment Algorithm would have resulted in 88.4% of cases receiving appropriate antibiotic therapy Vs. 78.1% by standard of care. Great work! https://t.co/Ncv5zpx1wC pic.twitter.com/NFioDqIDdb
Impact of a diagnostics-driven antifungal stewardship programme in a UK tertiary referral teaching hospital | Journal of Antimicrobial Chemotherapy | Oxford Academic https://t.co/qZ75MfzU6Y
— Mycology Reference Centre Manchester (@MycologyRefManc) September 24, 2018
A NEW RCT @JAMA_current
— Antibiotic Steward (@ABsteward) September 16, 2018
Levofloxacin prophylaxis significantly ⬇️ the risk of bacteremia in children with ALL/AML on intensive chemotherapy BUT not in those undergoing HSCT
Surprisingly levo prophylaxis ⬇️ likelihood of having a +ve test for C.Diff.https://t.co/NFdmXmfixx pic.twitter.com/gR8oXNk1V4
NEW.🔥🔥in CID Considerations for Clinical Trials of Staphylococcus aureus Bloodstream Infection in Adults. A must read article by Dr. Thomas Holland @Duke_GIM and @hboucher3 https://t.co/evWCrfp0O7 pic.twitter.com/4TzfoKS9Sj
— Antibiotic Steward (@ABsteward) September 10, 2018
NEW🔥in IJAA.
— Antibiotic Steward (@ABsteward) September 20, 2018
An update on Staphylococcus aureus infective endocarditis from the International Society of Antimicrobial Chemotherapy(ISAC).https://t.co/xUoMlphqkZ pic.twitter.com/2PW4ynsySq
💥📄 New article looking at #antimicrobialstewardship in Costa Rica w/ ID pharmacist Dr. Diaz Madriz 📲 https://t.co/3WTWz1w651 ...We can all learn from each other! 👾🌎🌎🌏👾
— Tim Gauthier (@IDstewardship) September 4, 2018
cc: @CIDRAP @idpharmd @ABsteward @pahowho @ehealthpaho @khalideljaaly @IDPharmacist @BRxAD @jpogue1 pic.twitter.com/l8uXCxLpo9
💥New article! Insights on @MerinoTrial published yesterday from lead investigator @padstamundo 📲 https://t.co/aduN2whaSL #MerinoTrial #BadBugs #OpenAccess
— Tim Gauthier (@IDstewardship) September 12, 2018
cc: @BWDionne @julie_justo @IDPharmacist @ConanMacDougall @DosingMatters @PaulSaxMD @CIDRAP @CRE_REDUCE @AusAntibiotics pic.twitter.com/d0G2nGZfha
NEW 🔥 in @JAMA_current by @hboucher3
— Antibiotic Steward (@ABsteward) September 25, 2018
Algorithm-Based Therapy vs Usual Care on Clinical Success and Serious Adverse Events in Patients With Staphylococcal Bacteremia.
A Randomized Clinical Trialhttps://t.co/t7bSTPNuPc pic.twitter.com/uL7Z1T7zTN
Very interesting!
— Antibiotic Steward (@ABsteward) September 26, 2018
FQ exposure promotes Carbapenem resistance🤔
Fluoroquinolone prophylaxis in HM patients and HCT recipients is associated with breakthrough bacteremia with meropenem non-susceptible P. aeruginosa strains. NEW 🔥 in CID by @romneyinla https://t.co/RueVX0rl8E pic.twitter.com/LV0UiAavk5
NEW 🔥Moving Past the Routine Use of Macrolides— A new article Reviewing the Role of Combination Therapy in Community-Acquired Pneumonia.https://t.co/SYXSt3voF7 pic.twitter.com/r0r8XGvXYE
— Antibiotic Steward (@ABsteward) September 8, 2018
“ID is a puzzle with different solutions. If you know which drugs kill which organisms and where they distribute in the body, you can design a regimen to treat anything" @JGPharmD #IDquotes
— Antibiotic Steward (@ABsteward) September 16, 2018
More from @IDstewardship 👇https://t.co/yxHGlT2ko5
A NEW🔥🔥 study in CID found that recommended indications for urinary antigen testing for Streptococcus pneumoniae (SP) and Legionella pneumophia in IDSA CAP 2007 guidelines have poor sensitivity&specificity for identifying pts w positive tests. https://t.co/jC3iUkx7Xc pic.twitter.com/SveFXjIVyi
— Antibiotic Steward (@ABsteward) September 28, 2018
Finally🔥, a randomized controlled trial (CloCeBa) will compare cloxacillin & cefazolin for MSSA👾 bacteremia. Protocol available at @BMJ_Open : https://t.co/cj8sk5Juar pic.twitter.com/w764wrRPre
— Antibiotic Tweets (@khalideljaaly) September 8, 2018
Analysis of gut microbe relatedness from diverse mammalian species uncovers microbial clades that are conserved across mammals, as well as clades that are exclusive to and conserved among specific mammalian lineages @mbiojournal https://t.co/HfwggRG64O pic.twitter.com/ba6tlI2ez0
— ASM (@ASMicrobiology) September 14, 2018
This is the best hand hygiene edutainment video of all time; it’s official! Interesting @AJICJournal study evaluating YouTube edutainment videos https://t.co/lMiMzAvif0 https://t.co/1UB5i0Pjbi Bravo @claireekt and @julesstorr
— Jon Otter (@jonotter) September 21, 2018
📄 New! I was wondering about the differences between #eravacycline and #tigecycline. Looking at available data, here is a quick overview 📲 https://t.co/yE6UEhXrtA #Antibiotics #Xerava ...anything you would add, LMK! ...Also see 🔗 link in text to article by @PaulSaxMD pic.twitter.com/x2fQEztmCW
— Tim Gauthier (@IDstewardship) September 27, 2018
One of the must read papers of the year from @CollignonPeter & @CDDEP https://t.co/ZBqrupJ5g5 suggesting greatest impact on global prevalence AMR is from poor sanitation & contaminated potable water rather than antibiotic consumption @CIDRAP_ASP @Wellcome_AMR @ESGAP_ABS pic.twitter.com/LKFG7q8EAY
— Marc Mendelson (@SouthAfricanASP) September 2, 2018
Such an important study on whole genome sequencing of a pathogen, the future of how we can and should be treating infectious diseases https://t.co/VYTvcmxDq4 a "case study" in TB >10,000 genomes from 6 continents by @crypticproject @NEJM pic.twitter.com/2qFby4Yx5B
— Eric Topol (@EricTopol) September 26, 2018
Congratulations from @ESCMID
— ESCMID (@ESCMID) September 5, 2018
Otto Cars showed at #ECCMID2018 how collective global action is needed to manage the crisis of antimicrobial resistance by balancing innovation access and stewardship. His presentation can be found in our eLibrary. https://t.co/eIHbBh1Lhy https://t.co/LclWOpO6yM
Want some clinical context? Read the editorial by @eliowa and me. Treatment Algorithms for Staphylococcal Bacteremia
— Preeti Malani (@PreetiNMalani) September 25, 2018
Improving Clinical Care and Enhancing Antimicrobial Stewardship https://t.co/pVNNINvYgN
Invasive fungal infections were rare events until the mid-20th century. Why do fungi now kill more people each year than TB? @adahagan explores the ways technology has inadvertently increased fungal disease incidence, on the latest Microbial Sciences post: https://t.co/yDIiCmWocU pic.twitter.com/prGakioq9Z
— ASM (@ASMicrobiology) September 24, 2018
Interesting new paper on TB infection resisters.
— Megan Murray (@megan_b_murray) September 2, 2018
Long-term stability of resistance to latent M. tuberculosis infection in highly exposed TB household contacts in Kampala, Uganda | Clinical Infectious Diseases | Oxford Academic https://t.co/r7ZAcyjbmM
A NEW prospective study 🇫🇷 in CID
— Antibiotic Steward (@ABsteward) September 24, 2018
Pts with SSI in spinal surgery treated w IV Abx for 10 days only then when possible switch to PO Abx for reminder for a total of 6 weeks.
Success rate 92% 👍
Most common 👾MSSAhttps://t.co/X78jJbK50O pic.twitter.com/AEv4rD5D60
AMR Challenge Calls on World to Intensify Global Fight against Antibiotic Resistance - @ASMicrobiology commits to taking action to combat #AntimicrobialResistance #GlobalAMRChallenge https://t.co/znp26uDtyu pic.twitter.com/ZrlDz8h84i
— ASM Newsroom (@ASMnewsroom) September 25, 2018
Study looking at the feasibility of using telehealth to support antimicrobial stewardship at rural VAs with limited access to local ID expertise. #TeleStewardship 🤔https://t.co/HhNlZlZB1G pic.twitter.com/9QLuh1kQ71
— Jamie Kisgen (@KisgenUF) September 8, 2018
NEW 🔥🔥 @CDCgov :Outpatient Antibiotic Prescribing for Older Adults in the US: 2011 to 2014
— Antibiotic Steward (@ABsteward) September 17, 2018
The most commonly prescribed class :Quinolones 😱
followed by penicillins and macrolides.
Internists and family physicians prescribed 43% of antibiotic courses. https://t.co/yFcAxOejOu pic.twitter.com/kV1rCZtsdl
2 global burden of disease (GBD) studies now online. 1st, Estimates of the global, regional, and national morbidity, mortality, and aetiologies of #diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016 https://t.co/IucMyKlPYq
— The Lancet Infectious Diseases (@TheLancetInfDis) September 20, 2018
NEW🔥 consensus paper in CMI @ESCMID by 18 specialists in antibiotic stewardship @e_charani/@ASPphysician
— Antibiotic Steward (@ABsteward) September 6, 2018
Prioritising research areas for antibiotic stewardship programmes in hospitals:a behavioural perspective consensus paper. A must read article @ESCMID https://t.co/mT4xvm4dSX pic.twitter.com/mVz4gaCjOZ
🙌🏼 Another great resource from the folks @CDCgov @CDC_NCEZID here 📲 https://t.co/2o0ovCj5wu#FreeEducation #Antibiotics #SaveABX #StartSmartThenNarrow pic.twitter.com/PGop9IJVdr
— Tim Gauthier (@IDstewardship) September 5, 2018
The exciting new Commonwealth Partnerships for Antimicrobial Stewardship project will support local health workers in the fight against #AMR in Africa #CWPAMS find out more at: https://t.co/tSOxw8Vfei pic.twitter.com/1DIlvH4qKT
— The Fleming Fund (@FlemingFund) September 27, 2018
In which two ID fellows debate which "practice changing" paper to cover at ID Journal Club. (With thanks to @MerinoTrial for the inspiration.) Latest post:https://t.co/Bq9vSuHYQt
— Paul Sax (@PaulSaxMD) September 23, 2018
'US Food & Drug Administration launches strategy to address #antimicrobialresistance, with plans to spur drug development & alternative therapies, promote stewardship in animal health, advance surveillance, & enhance regulatory science' #StopSuperbugs https://t.co/Rh97kCvQ4S
— Antibiotic Action (@TheUrgentNeed) September 17, 2018
Telehealth Proves Valuable for Promoting Safe Antibiotic Prescribing Practices in Remote Healthcare Settings.
— ICHE Journal (@ICHEJournal) September 6, 2018
FirstView: https://t.co/SjSNlm8LJf
Press Release: https://t.co/r2GnEmx0cP pic.twitter.com/u5JhY3FDLJ
Created by Cameron Forbes. Last updated November 10, 2019 at 15:41 EST.